Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression
No abstract is available for this record.
Bibliographic context
Authors
Cecelia KellyMathieu FradetCatherine M. BostianAnna DonnellySara EllisMichael OstacherScott AaronsonTrisha Suppes
Watch author
Topics and keywords
psilocybin DepressionAnxietyPTSDChronic PainClinical TrialRandomized Controlled TrialTreatment-Resistant DepressionVeteransToxicity Randomized Controlled Trial Depression (economics)PsilocybinAnxietyClinical psychologyPsychiatryExploratory researchQuality of life (healthcare)PsychologyDepressive symptomsMedicineExperiential avoidancePlaceboPosttraumatic stressSeverity of illnessRandomized controlled trialLongitudinal studyClinical trialMajor depressive disorderRating scalePsychological intervention
Citation graph
0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.
Indexed papers citing this DOI
Related papers
S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depressionTrials · 2024-07-02Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary Clinical Trials · 2022-11-01